Bill
SB 1746
The bill requires clinician-administered drugs to meet DSCSA supply-chain controls and prohibits certain insurer/PBM practices, applying to many public and private plans starting 2
Status & Sponsors
- Introduced in the Illinois Senate (Sen. Cristina Castro, primary; Sen. Christopher Belt, cosponsor).
- Introduced Feb 2025 (Senate bill text filed Feb 5, 2025 in the 104th General Assembly).
- Companion: HB 2954.
- Applies to health benefit plans amended, delivered, issued, or renewed on or after January 1, 2026 (per bill synopsis).
- Department of Insurance authorized to adopt implementing rules as needed.
Purpose / Intent
- To regulate how health benefit plans, insurers and pharmacy benefit managers (PBMs) handle clinician‑administered drugs (drugs that are administered by a clinician rather than dispensed directly to the enrollee). The bill (1) prohibits certain insurer/PBM practices regarding these drugs and (2) requires clinician‑administered drugs to meet federal supply chain security and distribution controls.
Key Provisions
- New insurance code provision (creates 215 ILCS 5/356z.26a or similarly numbered section):
- Prohibits a health benefit plan, its contracted pharmacy benefit manager, or related entities from engaging in — or requiring an enrollee to engage in — specified prohibited acts with respect to clinician‑administered drugs. (The bill text identifies these prohibited acts; the introduced synopsis references but the excerpt is truncated.)
- Requires that a “clinician‑administered drug” meet the supply chain security controls and chain of distribution established under the federal Drug Supply Chain Security Act (DSCSA).
- Authorizes the Illinois Department of Insurance to adopt rules necessary to implement these provisions.
- Amends multiple Illinois statutes so public and governmental plans must comply:
- State Employees Group Insurance Act of 1971
- Counties Code
- Illinois Municipal Code
- School Code
- Health Maintenance Organization Act
- Voluntary Health Services Plans Act
— Each of these is amended to require policies/programs covered by those Acts to conform to the new clinician‑administered drug provisions of the Illinois Insurance Code.
- Definitions: The bill includes or references definitions for terms used in the new provisions (full definitions appear in the bill text).
Who Is Affected
- Private insurers and group health plans that cover clinician‑administered drugs.
- Pharmacy benefit managers and contracted PBMs.
- Clinicians and health care providers who administer drugs to patients.
- Pharmacies and entities in the distribution chain (must meet DSCSA controls).
- Public employer plans and local government self‑insured plans (states, counties, municipalities, school districts) — these statutes are amended to require compliance.
Potential Impact
- Aligns state requirements with the federal DSCSA, potentially increasing documentation and traceability obligations across the supply chain for clinician‑administered products.
- Imposes new compliance responsibilities on insurers and PBMs (contracting, benefit design, claims/payment processes) and may constrain certain PBM or plan practices related to clinician‑administered therapies.
- Affects public employer and local government plans by explicitly requiring the same coverage and compliance rules.
- Implementation will be shaped by Department of Insurance rulemaking.
Procedural / Timing Notes
- The bill’s substantive coverage for private plans applies to policies amended, delivered, issued, or renewed on or after January 1, 2026.
- Department of Insurance rulemaking authority is included to clarify implementation details.
- For the latest status (committee referrals, floor action, enactment), consult the Illinois General Assembly bill tracker or legislative journals; the provided materials include multiple procedural entries (introduced, committee referrals, hearings) and companion bill references.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
